Literature DB >> 20740606

Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.

Gabrielle van der Velde1, Ba' Pham, Márcio Machado, Luciano Ieraci, William Witteman, Claire Bombardier, Murray Krahn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 20740606     DOI： 10.1002/acr.20338

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN： 2151-464X            Impact factor:   4.794


× No keyword cloud information.
  21 in total

Review 1.  Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Authors:  Eleanor M Heather; Katherine Payne; Mark Harrison; Deborah P M Symmons
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

2.  Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question.

Authors:  Jinoos Yazdany; Gabriela Schmajuk; Mark Robbins; David Daikh; Ashley Beall; Edward Yelin; Jennifer Barton; Adam Carlson; Mary Margaretten; Joann Zell; Lianne S Gensler; Victoria Kelly; Kenneth Saag; Charles King
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-03       Impact factor: 4.794

Review 3.  Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable Analysis.

Authors:  Nick Bansback; Eric Fu; Huiying Sun; Daphne Guh; Wei Zhang; Diane Lacaille; Katherine Milbers; Aslam H Anis
Journal:  Curr Rheumatol Rep       Date:  2017-09       Impact factor: 4.592

4.  The ethical challenges in rheumatology.

Authors:  Emily J Mckeown
Journal:  Curr Rev Musculoskelet Med       Date:  2015-06

5.  A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

Authors:  Larry W Moreland; James R O'Dell; Harold E Paulus; Jeffrey R Curtis; Joan M Bathon; E William St Clair; S Louis Bridges; Jie Zhang; Theresa McVie; George Howard; Désirée van der Heijde; Stacey S Cofield
Journal:  Arthritis Rheum       Date:  2012-09

6.  Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.

Authors:  C Tzanetakos; A Tzioufas; A Goules; G Kourlaba; T Theodoratou; P Christou; N Maniadakis
Journal:  Rheumatol Int       Date:  2017-05-18       Impact factor: 2.631

7.  Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.

Authors:  M Cárdenas; S de la Fuente; M C Castro-Villegas; M Romero-Gómez; D Ruiz-Vílchez; J Calvo-Gutiérrez; A Escudero-Contreras; J R Del Prado; E Collantes-Estévez; P Font
Journal:  Rheumatol Int       Date:  2016-10-24       Impact factor: 2.631

Review 8.  Unresolved issues in biologic therapy for rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven
Journal:  Nat Rev Rheumatol       Date:  2011-03-08       Impact factor: 20.543

9.  Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china.

Authors:  Bin Wu; Alisa Wilson; Fang-fang Wang; Su-li Wang; Daniel J Wallace; Michael H Weisman; Liang-jing Lu
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

10.  Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.

Authors:  Bruno Fautrel; Benjamin Granger; Bernard Combe; Alain Saraux; Francis Guillemin; Xavier Le Loet
Journal:  Arthritis Res Ther       Date:  2012-11-19       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.